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Objective. We investigate whether low-protein diet would show beneﬁts in suppressing peritoneal transport rate in peritoneal
dialysis(PD)patients.Methods. Thisisasupplementedanalysisofourpreviouslypublishedtrial,whichrandomized60PDpatients
to receive low- (LP: dietary protein intake of 0.6–0.8g/kg/d), keto-acid-supplemented low- (sLP: 0.6–0.8g/kg/d with 0.12g/kg/d of
keto acids), or high- (HP: 1.0–1.2g/kg/d) protein diet and lasted for one year. In this study, the variations of peritoneal transport
rate were assessed. Results. While baseline D/Pcr (dialysate-to-plasma concentration ratio for creatinine at 4 hour) and D/D0glu
(dialysate glucose at 4 hour to baseline dialysate glucose concentration ratio) were similar, D/Pcr in group sLP was lower, and
D/D0glu was higher than those in the other two groups (P<0.05) at 12th month. D/D0glu increased (P<0.05), and D/Pcr tended
to decrease, (P = 0.071) in group sLP. Conclusions. Low-protein diet with keto acids may beneﬁt PD patients by maintaining
peritoneum at a lower transport rate.
1.Introduction
Since peritoneal equilibration test (PET) was introduced in
1987 [1], high transporters have been reported to show poor
clinical outcomes [2, 3], which are due to ﬂuid overload
[4], inﬂammation [5], or malnutrition [6], and so forth.
Peritoneal characteristics were determined by several factors
including genetic factors, peritoneal membrane anatomy,
eﬀective surface area, age, and uremia, which contribute to
the heterogeneity of peritoneal membrane function at the
onsetofPD[7–10].Exceptthoseinheritedhightransporters,
it was observed that peritoneal transport rate increased
with the time of treatment on PD [7]. During the PD
process, repeatedly exposure to inﬂammatory stimuli such as
glucose-based solutions and peritonitis episodes may lead to
persistent increase of peritoneal transport rate [11].
Many studies explored methods to prevent patient from
to be high transporters, thus preserve peritoneal function.
Recently, an interesting study found that a strict low-protein
diet (0.37 ± 0.05g/kg/d) during the predialysis period
may suppress peritoneal transport rate at induction of PD
[12]. However, it is unknown whether low-protein intake
during PD would show beneﬁts on peritoneal transport rate
maintenance. Since the current PD guidelines recommend
high-protein intake of no less than 1.2g/kg ideal body weight
(IBW)/day [13], very few clinical practice could answer
this question. Based on what we have found in our recent
published paper [14, 15], DPI of 0.6–0.8g/kg/d resulted in
neutralnitrogenbalance,maintainedgoodnutritionalstatus,
and improved plasma amino acids pattern in PD patients if
together with keto acid during 12 months of followup. We,
therefore, further assessed the eﬀect of dietary intervention2 International Journal of Nephrology
on peritoneal transport rate by analyzing PET results at
baseline and 12th month in the original PD cohort.
2. Methods
2.1. Study Design. The study population and methodology
have been previously described in detail [14, 15]. Brieﬂy,
60 PD patients with residual renal function (urine output
≥800ml/d or eGFR ≥2ml/min/1.73m2) who ﬁtted the
inclusion criteria were enrolled and randomized to low-
(LP:DPI of 0.6–0.8g/kgIBW/d), keto-acid-supplemented
low- (sLP:DPI of 0.6–0.8g/kgIBW/d with keto acids of
0.12g/kgIBW/d, Ketosteril; Fresenius Kabi Co., Ltd., Beijing,
China), or high- (HP:DPI of 1.0–1.2g/kgIBW/d) protein
group in the original study. The total energy intake (TEI),
including both from diets and PD glucose [16], was pre-
scribed as 35kcal/kgIBW for patients below 60 years of age
and 30kcal/kgIBW for the rest.
During the 12 months of followup, 7 patients dropped
out, thus, 53 patients ﬁnished the study (18 in group LP,
18 in group sLP, and 17 in group HP) and were analyzed
in the present study. PET was performed at baseline and
12th month as described by Twardowski et al. [1] using
2 liters of 2.5% dextrose solution for a 4-hour dwell. The
dialysate-to-plasma concentration ratio for creatinine at
4h o u r s( D / P cr) and dialysate glucose at 4 hours to the
baseline dialysate glucose concentration ratio (D/D0glu)w e r e
calculated. D/Pcr was used to classify the patients as high,
high average, low average, or low transporters [1]. The
estimated peritoneal glucose exposure was calculated from
thedialysisprescriptionasdescribedbyDaviesetal.[17].For
example, for a patient dialyzed by 4∗2Lexchanges(2∗1.5%,
1∗2.5%, and 1∗4.25%), daily peritoneal glucose exposure
would be 2∗30 + 1∗50 + 1∗85 = 195g.
During followup, angiotensin-converting enzyme inhi-
bitors (ACEIs) and/or angiotensin II receptor blockers
(ARBs) were applied to all the patients to control hyperten-
sion. Amino acids and other nutritional supplements were
avoided, and aminoglycosides were forbidden for patients
with residual renal function when infection occurred during
followup.
2.2. Statistical Analysis. Results are presented as mean ± SD
or median (interquartile range). Diﬀerences across groups
were assessed by ANOVA or Kruskal-Wallis test as appropri-
ate. Post hoc analysis was done using methods of Student-
Newman-Keuls (S-N-K) for ANOVA or Dunnett’s T3 for
Kruskal-Wallis test. Comparisons between time periods were
performed using paired t-test or Wilcoxon’s paired test.
Comparisons of numeration data were performed using the
Chi-square test. A P value <0.05 was considered statistically
signiﬁcant. All analyses were carried out with SPSS 11.0 for
windows statistical software (SPSS Inc., Chicago, Ill, USA).
3. Results
3.1. Baseline Data. Baseline data of the 53 patients were
shown in Table 1. Brieﬂy, there were no signiﬁcant diﬀer-
ences in any of the assessed parameters between the groups,
except that C-reactive protein (CRP) level was slightly higher
in group sLP than group LP (7.8 [3.0–15.0] versus 3.0 [1.0–
4.2]mg/l, P<0.05).
3.2.DietaryComplianceandComorbidities. As we previously
reported [14], DPI diﬀered signiﬁcantly during the whole
period between group sLP and the others (P<0.05). Group
LP achieved a signiﬁcantly lower protein intake than group
HP in months 6 and 10. TEI was similar among the three
groups during the study (P>0.05).
During the study, 8 peritonitis episodes occurred in the
53 patients (2 in group LP, 4 in group sLP, and 2 in group
HP, P = ns). While CRP level at baseline was slight higher
in group sLP than group LP, it was similar among the three
groups at 12th month (LP: 3.1 [3.0–3.2]mg/l, sLP: 3.1 [3.1–
3.9]mg/l, and HP: 3.2 [3.1–6.4]mg/l, P = ns).
3.3. Peritoneal Transport Rate. Figure 1 shows data of D/Pcr
and D/D0glu in the three groups at baseline and 12th month.
While baseline D/Pcr and D/D0glu were similar among the
three groups, at 12th month in group sLP, D/Pcr was
signiﬁcantly lower (sLP: 0.59 ± 0.09, LP: 0.70 ± 0.09, and
HP: 0.66 ± 0.12, P<0.05) and D/D0glu was higher (sLP: 0.49
± 0.08, LP: 0.42 ± 0.06, and HP: 0.43 ± 0.11, P<0.05) than
the other two groups.
During 12 month followup, D/D0glu increased (P<
0.05), and D/Pcr intended to decrease (P = 0.071) in group
sLP. Changes of both D/Pcr and D/D0glu in group sLP were
more noticeable than the other two groups during followup
(ΔD/Pcr:s L P :−0.04 [−0.13, 0.05], LP: 0.04 [−0.06, 0.14],
and HP: 0.03 [−0.02, 0.12], P<0.05; ΔD/D0glu:s L P :0 . 0 5
[0.01, 0.10], LP: −0.03 [−0.11, 0.06], and HP: −0.04 [−0.10,
0.05], P<0.05).
Table 2 shows distribution of peritoneal transport rate
classiﬁed by D/Pcr among the three groups. At baseline, all
of three groups showed similar peritoneal transport rate
distribution (P = 0.559). At 12th month (P = 0.175), the
peritoneal transport rate distribution in group sLP showed
a borderline diﬀerence from group LP (P = 0.060), and HP
(P = 0.088), which indicated that fewer patients in group
sLP, had higher peritoneal transport rate after 12 months
followup.
3.4.DialysisDoseandGlucoseExposure. AsshowninTable 3,
baseline PD dosage and PD glucose exposure were equal
among the three groups. During followup, patients in both
groups LP and HP tended to increase their PD dosage, while
those in group sLP kept stable. PD glucose exposure in both
group LP and HP increased signiﬁcantly (LP: 100 ± 31 to
114 ± 27g/d; HP: 110 ± 25 to 129 ± 37g/d, P<0.05 for
both), while in group sLP it kept stable (sLP: 107 ± 18 to 109
± 22g/d, P>0.05), which in turn leads to markedly lower
glucose exposure in group HP than group sLP at 12th month
(P<0.05).
4. Discussion
In this supplemented analysis of a prospective randomized
trial, we found that in stable PD patients, low-protein dietInternational Journal of Nephrology 3
Table 1: Baseline data of the 53 PD patients, grouped according to the diet that they asre randomized to.
Group LP (n = 18) Group sLP (n = 18) Group HP (n = 17)
Age (year) 52.5 ± 13.7 56.3 ± 11.5 50.4 ± 12.3
Gender(male:female) 6:12 9:9 10:7
Diabetic nephropathy (yes/no) 1/17 1/17 1/16
BMI (kg/m2) 21.1 ± 2.1 22.3 ± 3.0 22.2 ± 3.3
Height (cm) 161.8 ± 8.1 163.7 ± 7.7 164.2 ± 6.1
Kt/Vtotal 2.4 ± 0.6 2.2 ± 0.3 2.4 ± 0.4
PD duration (month) 5.6 (1.3–14.2) 11.8 (3.8–20.9) 5.5 (1.3–14.2)
Urine protein (g/d) 0.7 (0.4–1.5) 0.7 (0.5–1.3) 1.0 (0.4–1.4)
Urine volume (ml/d) 1444 ± 460 1153 ± 409 1208 ± 378
e-GFR (ml/min/1.73m2)4 . 3 ± 2.4 3.7 ± 2.2 4.5 ± 2.4
Ultraﬁltrational volume (mL/d) 0 (−240, 200) 130 (70, 610) 300 (−150, 425)
Serum CRP (mg/l) 3.0 (1.0–4.2) 7.8 (3.0–15.0)∗ 3.1 (2.8–6.4)
Serum albumin (g/l) 36.1 ± 3.2 37.4 ± 4.2 38.3 ± 2.8
Note: ∗P<0.05, compared with group LP. PD: peritoneal dialysis; BMI: body mass index; e-GFR: estimatedglomerular ﬁltration rate, calculated as an average
of the creatinine and urea clearances by 24-hour urine; CRP: C-reactive protein.
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Figure 1: Peritoneal equilibration test (PET) results in the 53 PD patients, grouped according to the diet that they are randomized to during
12 month followup. (a) shows D/Pcr (dialysate-to-plasma concentration ratio for creatinine at 4 hours). (b) shows D/D0glu (dialysate glucose
at 4 hours to baseline dialysate glucose concentration ratio). ∗P<0.05, compared with the other two groups. #P<0.05, compared with
baseline.
supplemented with keto acids seemed to impact peritoneal
characteristics. Indeed, after 12 months of followup, patients
on supplemented low-protein diet showed declined D/Pcr
and elevated D/D0glu compared with patients on either high-
protein diet or low-protein diet alone.
As peritoneal membrane function of solute clearance
and water removal is the basic rationale of PD therapy,
preservation of peritoneal function is critically important. It
is generally accepted that avoidance of repeated peritonitis
and control of inﬂammation are favorable to peritoneal
transport rate maintenance [5, 18]. Blockades of the rennin-
angiotensin-aldosterone system could mitigate peritoneal
inﬂammation and ﬁbrosis, thus preserve peritoneum func-
tion [19]. Some studies also found that residual renal func-
tion could contribute to peritoneal function maintenance
[5]. However, there are certain amount of publications
reportingtheelevatedtransportratewiththetimeonPD[7].
According to recent reports, the increasing use of automated
PD [20] and icodextrin-based PD solutions [21]c o u l dp a rt l y
overcome problems caused by ﬂuid overload and improve
the clinical outcome among high transporters. Continuous
ambulatoryperitoneal dialysis (CAPD)by dextrose solutions
is, however, the most widely used PD form in developing
countries such as China. Thus, studies on suppressing
peritoneal transport rate are still highly warranted.
Low-proteindiethasbeenadvisedforpredialysispatients
as it shows eﬀects in controlling uremic symptoms, retarding
renal function loss [22, 23], and postponing the initiation
of dialysis [24] by lowering the requirements for renal
nitrogen clearance and/or reducing proteinuria [25, 26].
Low-protein diet among predialysis patients may suppress
peritoneal transport rate at induction of PD which was4 International Journal of Nephrology
Table 2: Comparison of peritoneal transport rate distribution classiﬁed by D/Pcr among the 3 groups at baseline and 12th month.
Group LP (n = 18) Group sLP (n = 18) Group HP (n = 17)
Baseline 12th month Baseline 12th month Baseline 12th month
H 142001
H A 977689
L A 879976
L 000321
Table 3: Changes of PD dose and PD glucose exposure in the 53 PD patients, grouped according to the diet which they are randomized to
during 12 month followup.
Group LP (n = 18) Group sLP (n = 18) Group HP (n = 17)
PD dose (L/d) Baseline 6.0 ± 1.5 6.7 ± 1.2 6.8 ± 1.2
12th month 6.4 ± 1.1 6.7 ± 1.2 7.2 ± 1.0
PD glucose exposure (g/d) Baseline 100 ± 31 107 ± 18 110 ± 25
12th month 114 ± 27# 109 ±22 129 ±37∗,#
Note: ∗P<0.05, compared with group sLP. #P<0.05, compared with baseline.
recently reported by Hasegawa et al. [12]. In the present
study, we further conﬁrm that low-protein diet during PD
therapy beneﬁts patients regarding peritoneum preservation.
The exact mechanisms to explain this phenomenon are not
clear. One possible explanation is that low-protein diet is
associated with decreased expression of ﬁbrotic factors such
as transforming growth factor-beta (TGF-β)[ 27]. In fact, we
found that compared with the patients in group sLP, those
in the other two groups increased their PD dose and exposed
to more hypertonic solutions during 1 year of followup. The
increment use of bio-incompatible solution was reported to
stimulate the releasing of ﬁbrotic or inﬂammatory factors
[28] and resulted in increased peritoneal transport rate [29].
Secondly, uremia itself may also impact peritoneal transport
rate [30]. Low-protein diet reduces uremic wastes such as
urea, phosphate, and so forth, in either predialysis patients
[24] or PD patients [14], and, in turn, protects peritoneal
membrane. On the other hand, the beneﬁcial eﬀects of
residual renal function on peritoneal function maintenance
have been reported by diﬀerent studies [5, 31]; therefore,
better preservation of residual renal function in group sLP
[14] seems to be another explanation supporting current
results.
In addition, there are several other factors which may be
also involved in. It is well known that peritonitis episodes
[18] and inﬂammation [5] play an important role in the
increment of peritoneal permeability. Interestingly, patients
in group sLP maintained peritoneal membrane function
better during 12 months of followup in our study, even
though their baseline CRP level was signiﬁcantly higher
than others. The potential role of keto acids in peritoneum
preservation cannot be completely excluded in group sLP.
Furthermore, high transporters usually have greater albumin
loss through peritoneal cavity [32], which is conceptually
analogous to microalbuminuria in diabetic patients [33].
Though the present study did not investigate peritoneal
protein loss; however, we observed the decrement of urine
protein output in patients receiving keto-acid-supplemented
low-protein diet. The prescription of sLP may also suppress
peritoneal protein leakage in these patients.
There are several limitations in the present study that
need to be discussed. Firstly, the sample size of the study was
relatively small, and data of peritoneal transport rate as only
available on two time points, lack of data on protein loss and
TGF-β levelsindialysate,asitisonlyasupplementedanalysis
forourpreviousstudy.Secondly,thepatientsingroupLPdid
not manage their DPI consistently to the prescribed range.
Thus, we cannot diﬀerentiate in current study whether ben-
eﬁcial eﬀect on peritoneal function comes from low-protein
diet or the use of keto acid. Nevertheless, our data provides a
new clue for peritoneum preservation among PD patients.
In summary, our results showed that low-protein diet
(DPI of 0.6–0.8g/IBWkg/d) supplemented with keto acids
may beneﬁt PD patients by maintaining peritoneum at a
lower transport rate.
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